Maciej Krzakowski

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Systematic Review

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Translational lung cancer research

Discover oncology

Drugs of today (Barcelona, Spain : 1998)

This page only lists publications with an associated author ORCID identifier.

Publications

Dariusz Mirosław Kowalski, Magdalena Zaborowska-Szmi, Sebastian Szmit, Piotr Jaśkiewicz, Maciej Krzakowski
The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity. Translational lung cancer research 13 (6) (2024)
Dariusz Mirosław Kowalski, Magdalena Zaborowska-Szmi, Sebastian Szmit, Piotr Jaśkiewicz, Maciej Krzakowski
The combination of osimertinib and savolitinib as molecular inhibition of EGFR and MET receptors may be selected to provide maximum effectiveness and acceptable toxicity. Translational lung cancer research 13 (6) (2024)
Tomasz Macioch, Maciej Krzakowski, Klaudia Gołębiewska, Małgorzata Dobek, Natalia Warchałowska, Maciej Niewada
Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data. Discover oncology 15 (1) (2024)
Tomasz Macioch, Maciej Krzakowski, Klaudia Gołębiewska, Małgorzata Dobek, Natalia Warchałowska, Maciej Niewada
Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data. Discover oncology 15 (1) (2024)
Magdalena Zaborowska-Szmi, Sebastian Szmit, Maciej Krzakowski, Dariusz Mirosław Kowalski
Savolitinib for non-small cell lung cancer. Drugs of today (Barcelona, Spain : 1998) 59 (1) (2023)